162 related articles for article (PubMed ID: 24001168)
1. Telaprevir impairs renal function and increases blood ribavirin concentration during telaprevir/pegylated interferon/ribavirin therapy for chronic hepatitis C.
Karino T; Ozeki I; Hige S; Kimura M; Arakawa T; Nakajima T; Kuwata Y; Sato T; Ohmura T; Toyota J
J Viral Hepat; 2014 May; 21(5):341-7. PubMed ID: 24001168
[TBL] [Abstract][Full Text] [Related]
2. Telaprevir enhances ribavirin-induced anaemia through renal function impairment.
Cotte L; Barrail-Tran A; Vincent C; Valantin MA; Fournier I; Lacombe K; Chevaliez S; Aboulker JP; Taburet AM; Molina JM;
Antivir Ther; 2015; 20(5):479-86. PubMed ID: 25560644
[TBL] [Abstract][Full Text] [Related]
3. Renal dysfunction associated with telaprevir-containing triple therapy for chronic hepatitis C: is early prediction possible?
Rémy AJ; Lesgourgues B; Nalet B; Causse X; Henrion J; Denis J; Arotçarena R; Hagège H; Pariente A;
Eur J Gastroenterol Hepatol; 2014 Sep; 26(9):996-1002. PubMed ID: 25072384
[TBL] [Abstract][Full Text] [Related]
4. Adjusting the starting dose of telaprevir according to renal function decreases adverse effects and affects the sustained virological response rate.
Morihara D; Watanabe H; Takata K; Iwashita H; Tsuchiya N; Kunimoto H; Kuno S; Fukunaga A; Yotsumoto K; Tanaka T; Sakurai K; Hirano G; Yokoyama K; Nishizawa S; Yoshikane M; Anan A; Takeyama Y; Kitamura Y; Iwata K; Irie M; Shakado S; Sohda T; Sakisaka S
Eur J Gastroenterol Hepatol; 2015 Jan; 27(1):55-64. PubMed ID: 25370853
[TBL] [Abstract][Full Text] [Related]
5. Significant early higher ribavirin plasma concentrations in patients receiving a triple therapy with pegylated interferon, ribavirin and telaprevir.
Boglione L; De Nicolò A; Cusato J; Cariti G; Di Perri G; D'Avolio A
J Viral Hepat; 2014 Apr; 21(4):260-3. PubMed ID: 24597694
[TBL] [Abstract][Full Text] [Related]
6. Clinical milestones for the prediction of severe anemia by chronic hepatitis C patients receiving telaprevir-based triple therapy.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Oct; 59(4):667-74. PubMed ID: 23707372
[TBL] [Abstract][Full Text] [Related]
7. Does elevation of serum creatinine in patients with chronic hepatitis C under therapy of telaprevir mean renal impairment?
Matsui K; Kamijo-Ikemori A; Sugaya T; Ikeda H; Okuse C; Shibagaki Y; Yasuda T; Kimura K
Nephrology (Carlton); 2015 Nov; 20(11):843-8. PubMed ID: 25998031
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.
Sulkowski MS; Sherman KE; Dieterich DT; Bsharat M; Mahnke L; Rockstroh JK; Gharakhanian S; McCallister S; Henshaw J; Girard PM; Adiwijaya B; Garg V; Rubin RA; Adda N; Soriano V
Ann Intern Med; 2013 Jul; 159(2):86-96. PubMed ID: 23685940
[TBL] [Abstract][Full Text] [Related]
9. Telaprevir-S isomer enhances ribavirin exposure and the ribavirin-related haemolytic anaemia in a concentration-dependent manner.
De Nicolò A; Boglione L; Ciancio A; Cusato J; Strona S; Cardellino CS; Abdi AM; Cariti G; Troshina G; Caviglia GP; Smedile A; Rizzetto M; Di Perri G; D'Avolio A
Antiviral Res; 2014 Sep; 109():7-14. PubMed ID: 24956496
[TBL] [Abstract][Full Text] [Related]
10. SLC29A1 polymorphism and prediction of anaemia severity in patients with chronic hepatitis C receiving triple therapy with telaprevir.
Milazzo L; Peri AM; Mazzali C; Magni C; Calvi E; De Nicolò A; Clementi E; Cheli S; D'Avolio A; Antinori S; Falvella FS
J Antimicrob Chemother; 2015 Apr; 70(4):1155-60. PubMed ID: 25583751
[TBL] [Abstract][Full Text] [Related]
11. Telaprevir is effective given every 12 h at 750 mg with pegylated interferon-α2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT.
Kawakami Y; Suzuki F; Karino Y; Toyota J; Kumada H; Chayama K
Antivir Ther; 2014; 19(3):277-85. PubMed ID: 24192751
[TBL] [Abstract][Full Text] [Related]
12. The prospective randomized study on telaprevir at 1500 or 2250 mg with pegylated interferon plus ribavirin in Japanese patients with HCV genotype 1.
Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Yamada A; Oshita M; Kaneko A; Suzuki K; Inui Y; Tamura S; Yoshihara H; Imai Y; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
J Gastroenterol; 2015 Mar; 50(3):313-22. PubMed ID: 24806033
[TBL] [Abstract][Full Text] [Related]
13. A Randomized Study of Peginterferon Lambda-1a Compared to Peginterferon Alfa-2a in Combination with Ribavirin and Telaprevir in Patients with Genotype-1 Chronic Hepatitis C.
Flisiak R; Shiffman M; Arenas J; Cheinquer H; Nikitin I; Dong Y; Rana K; Srinivasan S
PLoS One; 2016; 11(10):e0164563. PubMed ID: 27749900
[TBL] [Abstract][Full Text] [Related]
14. Peginterferon Lambda-1a/Ribavirin with Daclatasvir or Peginterferon Alfa-2a/Ribavirin with Telaprevir for Chronic Hepatitis C Genotype 1b.
Flisiak R; Kawazoe S; Znoyko O; Assy N; Gadano A; Kao JH; Lee KS; Zwirtes R; Portsmouth S; Dong Y; Xu D; Kumada H; Srinivasan S
J Interferon Cytokine Res; 2016 Nov; 36(11):635-643. PubMed ID: 27327078
[TBL] [Abstract][Full Text] [Related]
15. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study.
Ogawa E; Furusyo N; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
Aliment Pharmacol Ther; 2013 Nov; 38(9):1076-85. PubMed ID: 24099469
[TBL] [Abstract][Full Text] [Related]
16. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
[TBL] [Abstract][Full Text] [Related]
17. Influence of ITPA polymorphisms on decreases of hemoglobin during treatment with pegylated interferon, ribavirin, and telaprevir.
Suzuki F; Suzuki Y; Akuta N; Sezaki H; Hirakawa M; Kawamura Y; Hosaka T; Kobayashi M; Saito S; Arase Y; Ikeda K; Kobayashi M; Chayama K; Kamatani N; Nakamura Y; Miyakawa Y; Kumada H
Hepatology; 2011 Feb; 53(2):415-21. PubMed ID: 21246582
[TBL] [Abstract][Full Text] [Related]
18. Telaprevir for HIV/hepatitis C virus-coinfected patients failing treatment with pegylated interferon/ribavirin (ANRS HC26 TelapreVIH): an open-label, single-arm, phase 2 trial.
Cotte L; Braun J; Lascoux-Combe C; Vincent C; Valantin MA; Sogni P; Lacombe K; Neau D; Aumaitre H; Batisse D; de Truchis P; Gervais A; Michelet C; Morlat P; Vittecoq D; Rosa I; Bertucci I; Chevaliez S; Aboulker JP; Molina JM;
Clin Infect Dis; 2014 Dec; 59(12):1768-76. PubMed ID: 25139963
[TBL] [Abstract][Full Text] [Related]
19. Patients treated with first-generation HCV protease inhibitors exhibit high ribavirin concentrations.
Bodeau S; Nguyen-Khac E; Solas C; Bennis Y; Capron D; Duverlie G; Brochot E
J Clin Pharmacol; 2015 May; 55(5):517-24. PubMed ID: 25535910
[TBL] [Abstract][Full Text] [Related]
20. Weight loss during telaprevir-based triple therapy due to telaprevir-induced appetite loss.
Nomura H; Miyagi Y; Tanimoto H; Kawano A; Yamashita N
Intern Med; 2014; 53(22):2567-73. PubMed ID: 25400176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
